L-type calcium channel blockers at therapeutic concentrations are not linked to CRAC channels and heart failure
Amlodipine has been used as a front-line anti-hypertensive therapy for decades by virtue of blocking voltage-operated calcium channels with high affinity and specificity. Recently, the safety of amlodipine has been questioned, as it was reported to activate Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> (CRAC) channels and increase the risk of heart failure. Here we show, using a variety of approaches, that amlodipine does not activate CRAC channels at therapeutic concentrations. Combined with our previous meta-analysis, our study should reassure physicians that amlodipine should continue to be prescribed for treating hypertension.
Authors
- Sandosh Padmanabhan (ORCID: https://orcid.org/0000-0003-3869-5808)
- Min Shi (ORCID: https://orcid.org/0000-0001-8265-5307)
- Gary S. Bird (ORCID: https://orcid.org/0000-0003-1389-8748)
- Charles J. Tucker (ORCID: https://orcid.org/0009-0005-4329-7910)
- Anant B. Parekh
- Yu‐Ping Lin
- Geoffrey A. Mueller (ORCID: https://orcid.org/0000-0001-8361-5323)
Institutions
- National Institute of Environmental Health Sciences (US)
- University of Glasgow (GB)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Clinical and Experimental Hypertension
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1080/10641963.2025.2515924
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Environmental Health Sciences